IDH1-IN-1

CAS No. 1355326-21-4

IDH1-IN-1( Mutant IDH1-IN-1 )

Catalog No. M11452 CAS No. 1355326-21-4

Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 65 In Stock
2MG 37 In Stock
5MG 62 In Stock
10MG 95 In Stock
25MG 183 In Stock
50MG 257 In Stock
100MG 375 In Stock
200MG 507 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    IDH1-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
  • Description
    Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1(Example 135).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Mutant IDH1-IN-1
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    mutant IDH1 R132H
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1355326-21-4
  • Formula Weight
    498.59
  • Molecular Formula
    C30H31FN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(NC1CCCCC1)C(N(C(CN2C3=CC=CC=C3N=C2)=O)C4=CC=CC(F)=C4)C5=CC=CC=C5C
  • Chemical Name
    2-(N-[2-(Benzimidazol-1-yl)acetyl]-3-fluoroanilino)-N-cyclohexyl-2-(2-methylphenyl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Janeta Popovici-Muller, et al. Patent WO2012009678 A
molnova catalog
related products
  • ASLAN003

    ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML.

  • Carbenoxolone

    Carbenoxolone is an inhibitor of 11β-HSD and gap junction connexin channels. Carbenoxolone inhibits macrophage migration into atria and prevents the development of fatty liver disease.

  • PHGDH-IN-3

    PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 2.8 μM against PHGDH, and it can be used in cancer research.